1-Naphthohydroxamic acid (Compound 2) 是一种有效的,选择性的HDAC8抑制剂,IC50为 14 μM。1-Naphthohydroxamic acid 对HDAC8的选择性高于 I 类 HDAC1 和 II 类 HDAC6 (IC50>100 μM)。1-Naphthohydroxamic acid 不会增加整体组蛋白 H4 的乙酰化,也不会降低总细胞内 HDAC 的活性。1-Naphthohydroxamic acid 可诱导微管蛋白乙酰化。
生物活性 | 1-Naphthohydroxamic acid (Compound 2) is a potent and selectiveHDAC8inhibitor with anIC50of 14 μM. 1-Naphthohydroxamic acid is more selectively forHDAC8than class IHDAC1and class IIHDAC6(IC50>100 μM). 1-Naphthohydroxamic acid does not increase global histone H4 acetylation and also does not reduce total intracellularHDACactivity[1][2].1-Naphthohydroxamic acid can induce tubulin acetylation[3]. |
IC50& Target[1] | HDAC8 14 μM (IC50) | HDAC1 >100 μM (IC50) | HDAC6 >100 μM (IC50) |
|
体外研究 (In Vitro) | 1-Naphthohydroxamic acid (compound 2; 20-40 μM; 0-144 hours; BE(2)-C, SK-N-BE(2) and SH-SY5Y cells) treatment reduces cell numbers in a concentration-dependent manner[2]. 1-Naphthohydroxamic acid (compound 2) at concentrations in the range of its in vitro IC50against HDAC8 results in reduced cell density and outgrowth of neurite-like structures that stained positive for neurofilament.1-Naphthohydroxamic acid reduces the formation of clones in soft-agar concentration dependently[2]. When either cell type (HeLa and HEK293 cells) is treated with 1-Naphthohydroxamic acid (compound 2; 0.8 μM, 4 μM, 20 μM or 100 μM), only tubulin becomes hyperacetylated[1].
Cell Proliferation Assay[2] Cell Line: | BE(2)-C, SK-N-BE(2) and SH-SY5Y cells | Concentration: | 20 μM, 40 μM | Incubation Time: | 0 hours, 24 hours, 48 hours, 72 hours, 96 hours, and 144 hours | Result: | Reduced cell numbers in a concentration-dependent manner. |
|
体内研究 (In Vivo) | Dose-limiting toxicities (DLTs) of 1-Naphthohydroxamic acid (compound 2; 0-40 mg/kg; intraperitoneal injection; daily; for 10 day; NMRIFoxn1nude mice) include weight loss and signs of liver toxicity, as evidenced by elevated plasma liver enzymes and detection of necrotic areas on histological liver examination. 1-Naphthohydroxamic acid has the maximum tolerable doses at 50 mg/kg per day. At these concentrations, neither body weight nor blood parameters are critically changed[3]. Pharmacokinetic studies after intraperitoneal administration of the inhibitors identified the half-life of 1-Naphthohydroxamic acid to be ~15 min, with a plasma peak concentration of ~30 μM[3].
Animal Model: | NMRIFoxn1nude mice[3] | Dosage: | 0 mg/kg, 50 mg/kg, 100mg/kg, 200 mg/kg, 300 mg/kg 400 mg/kg | Administration: | Intraperitoneal injection; daily; for 10 days | Result: | Dose-limiting toxicities (DLTs) included weight loss and signs of liver toxicity, as evidenced by elevated plasma liver enzymes and detection of necrotic areas on histological liver examination. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 125 mg/mL(667.77 mM;Need ultrasonic) 配制储备液 1 mM | 5.3422 mL | 26.7108 mL | 53.4217 mL | 5 mM | 1.0684 mL | 5.3422 mL | 10.6843 mL | 10 mM | 0.5342 mL | 2.6711 mL | 5.3422 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 |